139 related articles for article (PubMed ID: 33378376)
21. ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.
Williams CS; Bernard JK; Demory Beckler M; Almohazey D; Washington MK; Smith JJ; Frey MR
Carcinogenesis; 2015 Jul; 36(7):710-8. PubMed ID: 25916654
[TBL] [Abstract][Full Text] [Related]
22. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.
Takahashi Y; Fukuda Y; Yoshimura J; Toyoda A; Kurppa K; Moritoyo H; Belzil VV; Dion PA; Higasa K; Doi K; Ishiura H; Mitsui J; Date H; Ahsan B; Matsukawa T; Ichikawa Y; Moritoyo T; Ikoma M; Hashimoto T; Kimura F; Murayama S; Onodera O; Nishizawa M; Yoshida M; Atsuta N; Sobue G; ; Fifita JA; Williams KL; Blair IP; Nicholson GA; Gonzalez-Perez P; Brown RH; Nomoto M; Elenius K; Rouleau GA; Fujiyama A; Morishita S; Goto J; Tsuji S
Am J Hum Genet; 2013 Nov; 93(5):900-5. PubMed ID: 24119685
[TBL] [Abstract][Full Text] [Related]
23. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.
Tvorogov D; Sundvall M; Kurppa K; Hollmén M; Repo S; Johnson MS; Elenius K
J Biol Chem; 2009 Feb; 284(9):5582-91. PubMed ID: 19098003
[TBL] [Abstract][Full Text] [Related]
24. An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.
Chakroborty D; Ojala VK; Knittle AM; Drexler J; Tamirat MZ; Ruzicka R; Bosch K; Woertl J; Schmittner S; Elo LL; Johnson MS; Kurppa KJ; Solca F; Elenius K
Cancer Res Commun; 2022 Jan; 2(1):10-27. PubMed ID: 36860695
[TBL] [Abstract][Full Text] [Related]
25. Activation of NRG1-ERBB4 signaling potentiates mesenchymal stem cell-mediated myocardial repairs following myocardial infarction.
Liang X; Ding Y; Zhang Y; Chai YH; He J; Chiu SM; Gao F; Tse HF; Lian Q
Cell Death Dis; 2015 May; 6(5):e1765. PubMed ID: 25996292
[TBL] [Abstract][Full Text] [Related]
26. Stimulation of the four isoforms of receptor tyrosine kinase ErbB4, but not ErbB1, confers cardiomyocyte hypertrophy.
Wang Z; Chan HW; Gambarotta G; Smith NJ; Purdue BW; Pennisi DJ; Porrello ER; O'Brien SL; Reichelt ME; Thomas WG; Paravicini TM
J Cell Physiol; 2021 Dec; 236(12):8160-8170. PubMed ID: 34170016
[TBL] [Abstract][Full Text] [Related]
27. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.
Mill CP; Gettinger KL; Riese DJ
Exp Cell Res; 2011 Feb; 317(4):392-404. PubMed ID: 21110957
[TBL] [Abstract][Full Text] [Related]
28. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
29. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
30. miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4.
Liang H; Liu M; Yan X; Zhou Y; Wang W; Wang X; Fu Z; Wang N; Zhang S; Wang Y; Zen K; Zhang CY; Hou D; Li J; Chen X
J Biol Chem; 2015 Jan; 290(2):926-40. PubMed ID: 25391651
[TBL] [Abstract][Full Text] [Related]
31. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis.
Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
[TBL] [Abstract][Full Text] [Related]
32. Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo.
Bernard JK; McCann SP; Bhardwaj V; Washington MK; Frey MR
J Biol Chem; 2012 Nov; 287(47):39850-8. PubMed ID: 23033483
[TBL] [Abstract][Full Text] [Related]
33. The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation.
Hoesl C; Röhrl JM; Schneider MR; Dahlhoff M
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):958-966. PubMed ID: 29410073
[TBL] [Abstract][Full Text] [Related]
34. Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells.
Wali VB; Haskins JW; Gilmore-Hebert M; Platt JT; Liu Z; Stern DF
Mol Cancer Res; 2014 Aug; 12(8):1140-55. PubMed ID: 24829397
[TBL] [Abstract][Full Text] [Related]
35. Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
Zaraei SO; Sbenati RM; Alach NN; Anbar HS; El-Gamal R; Tarazi H; Shehata MK; Abdel-Maksoud MS; Oh CH; El-Gamal MI
Eur J Med Chem; 2021 Nov; 224():113674. PubMed ID: 34237622
[TBL] [Abstract][Full Text] [Related]
36. miR-433 Inhibits Glioblastoma Progression by Suppressing the PI3K/Akt Signaling Pathway Through Direct Targeting of
Jiang H; Su Z; Hu W; Yuan X; Yu T; Yang J; Xiao X; Zheng S; Lin B
OMICS; 2023 May; 27(5):215-226. PubMed ID: 37196148
[TBL] [Abstract][Full Text] [Related]
37. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.
Langdon CG; Held MA; Platt JT; Meeth K; Iyidogan P; Mamillapalli R; Koo AB; Klein M; Liu Z; Bosenberg MW; Stern DF
Pigment Cell Melanoma Res; 2015 Jul; 28(4):417-30. PubMed ID: 25854919
[TBL] [Abstract][Full Text] [Related]
38. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2.
Crovello CS; Lai C; Cantley LC; Carraway KL
J Biol Chem; 1998 Oct; 273(41):26954-61. PubMed ID: 9756944
[TBL] [Abstract][Full Text] [Related]
39. Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy.
Sahu A; Patra PK; Yadav MK; Varma M
J Recept Signal Transduct Res; 2017 Oct; 37(5):470-480. PubMed ID: 28670936
[TBL] [Abstract][Full Text] [Related]
40. Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model.
Lu Y; Boswell W; Boswell M; Klotz B; Kneitz S; Regneri J; Savage M; Mendoza C; Postlethwait J; Warren WC; Schartl M; Walter RB
Sci Rep; 2019 Jan; 9(1):530. PubMed ID: 30679619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
